Nektar Therapeutics (NAS:NKTR)
$ 1.085 -0.095 (-8.05%) Market Cap: 200.14 Mil Enterprise Value: 81.43 Mil PE Ratio: 0 PB Ratio: 4.02 GF Score: 59/100

Nektar Therapeutics Conference Call for Analysts at EULAR Transcript

Jun 05, 2020 / 03:00PM GMT
Release Date Price: $22.27 (-3.59%)
Operator

Ladies and gentlemen, thank you for standing by. And welcome to the webcast conference call for analysts at EULAR. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Vivian Wu, part of the Investor Relations team at Nektar. Ma'am, you may begin.

Vivian Wu;Investor Relations

Good morning, everyone, and thank you for joining us on today's analyst call to review data presented for NKTR-358 at the Virtual 2020 Annual European Congress of Rheumatology, also known as 2020 EULAR.

Joining us today are Dr. Jonathan Zalevsky, our Chief R&D Officer; Dr. Brian Kotzin, our Head of Immunology at Nektar and Program Lead for NKTR-358 with our partner, Eli Lilly and Company; and Jennifer Ruddock, our Head of Strategy and Corporate Affairs.

JZ will present some background material and then review the data presented at the Congress, and then we will open it up to Q&A.

Before we start, I'll remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot